Trial Condition(s):

Cancer

BAY2757556, no drug Larotrectinib related - OS (VOYAGER-1)

Bayer Identifier:

20703

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The primary objective of the study is to evaluate overall survival for cancer patients with NTRK gene fusion and cancer patients without any NTRK gene mutations including gene fusion or other rearrangements under current standard of care.
Secondary objectives comprise the frequency of NTRK fusions, other NTRK re-arrangements, patient characteristics, treatment patterns, overall survival for patients with other NTRK gene rearrangements and overall survival after the start of antineoplastic therapy.

Inclusion Criteria
- At least one documented clinical visit in the Flatiron network on or after January 1, 2011 and on or prior to July 31, 2018;
 - Underwent Comprehensive Genomic Profiling (CGP) testing by FMI on or prior to July 31, 2018 using a baitset that includes the coding exons of the NTRK gene family (NTRK1, NTRK2, NTRK3).
Exclusion Criteria
- Patients with death dates prior to 2012 were excluded *
Eligible patients were classified into the following four cohorts based on CGP-reported NTRK gene fusion status and tumor type. 
* FMI began NGS test in August 2012. As a result, any patient with a death date before the start of 2012 would most likely be an error, so they are excluded to avoid any data issue.

Trial Summary

Enrollment Goal
15971
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Unspecified
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many locations, United States

Status
Completed
 

Trial Design